Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Quinidine and high-amplification ECG]

B Brembilla-Perrot1, D Beurrier, L Jacquemin

  • 1Service de Cardiologie A, CHU de, Brabois, Vandaeuvre-Les-Nancy.

Annales De Cardiologie Et D'Angeiologie
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aminoglycoside-induced sensorineural hearing loss in pediatric cystic fibrosis patients: A retrospective cohort study.

Heliyon·2024
Same author

Sequential dual-site High-Definition transcranial Direct Current Stimulation (HD-tDCS) treatment in chronic subjective tinnitus: study protocol of a double-blind, randomized, placebo-controlled trial.

Trials·2019
Same author

Predictive factors of speech understanding in adults with cochlear implants.

B-ENT·2018
Same author

Does syncope require rhythmic and non-rhythmic evaluation in patients with previous MI?

Heart Asia·2016
Same author

[Arrhythmia and muscular exercise intolerance revealing lamin genetic defect in a young adult].

La Revue de medecine interne·2014
Same author

Prevalence, causes of reappearance of symptoms or preexcitation syndrome after ablation of accessory pathway and management.

Annales de cardiologie et d'angeiologie·2014

High-amplification ECG (HA ECG) effectively monitors ventricular tachycardia treatment. However, quinidine therapy alters HA ECGs, and these changes do not predict treatment success for arrhythmias.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Technology

Context:

  • High-amplification ECG (HA ECG) is a standard tool for assessing ventricular tachycardia.
  • Quinidine is a Class I antiarrhythmic agent used to manage cardiac arrhythmias.
  • Understanding the impact of antiarrhythmic drugs on ECG parameters is crucial for patient management.

Purpose:

  • To investigate the effects of quinidine on high-amplification ECG (HA ECG) parameters in patients with ventricular tachycardia.
  • To determine if HA ECG modifications correlate with the antiarrhythmic efficacy of quinidine.
  • To assess whether quinidine therapy can induce changes in HA ECG findings.

Summary:

  • This study evaluated 26 heart disease patients with ventricular tachycardia receiving quinidine (300-600 mg).

Related Experiment Videos

  • Programmed ventricular stimulation and HA ECG were recorded before and during treatment.
  • HA ECG tracings showed significant modifications (e.g., increased QRS duration, decreased RMS 40, increased LAS) irrespective of whether ventricular tachycardia induction became negative.
  • Abnormalities in HA ECG developed in some patients during quinidine therapy, even with initially normal tracings.
  • Importantly, the observed HA ECG changes did not predict the effectiveness of quinidine in suppressing inducible ventricular tachycardia and did not detect drug-induced proarrhythmia in some cases.

    • Impact:

    • Quinidine therapy significantly alters HA ECG parameters in patients with ventricular tachycardia.
    • Changes in HA ECG tracings during quinidine treatment do not reliably predict therapeutic success.
    • These findings highlight the limitations of HA ECG in assessing the efficacy of Class I antiarrhythmic agents and suggest that HA ECG modifications are independent of the drug's effect on arrhythmia induction.